CN112236200A

CN112236200A - Soothing reactive skin by topical application of seed oil of at least one Umbelliferae plant

Info

Publication number: CN112236200A
Application number: CN201980037309.9A
Authority: CN
Inventors: 凯瑟琳·克恩
Original assignee: Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Current assignee: Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority date: 2018-05-04
Filing date: 2019-05-02
Publication date: 2021-01-15
Also published as: WO2019211563A1; JP2021522287A; FR3080770A1; EP3787756A1; KR20210003865A; FR3080770B1

Abstract

Use of at least one oil of at least one seed of an Umbelliferae plant as a topically applicable cosmetic active ingredient for preventing or slowing down the appearance of sensory disorders on the human skin of a sensitive person.

Description

Soothing reactive skin by topical application of seed oil of at least one Umbelliferae plant

The present invention relates to the use of at least one oil from seeds of plants of the Umbelliferae family for preventing or slowing down the appearance of sensory disorders in sensitive human skin.

The skin is the first protective barrier of the human body against the environment. It is therefore subject to many external attacks which may lead to uncomfortable skin reactions or, even in the case of very intense or more severe reactions, to phenomena of skin irritation and/or inflammation. The unpleasant skin reaction may be caused, inter alia, by contact with chemical products (e.g. cleansers, perms, hair dyes), or by mechanical effects (e.g. shaving, scrubbing, peeling, depilation), or by temperature, weather, uv radiation or even atmospheric pollution.

Sensitive or reactive skin is more susceptible to these external attacks. Sensitive or reactive skin is a condition affecting many people: approximately 50% of people (60% women, 40% men) report reactive skin. It has recently been defined as a syndrome defined by "discomfort (stinging, burning, pain, itching and tingling) in response to stimuli that should not normally cause such sensations. These sensations cannot be explained by lesions attributable to any skin disease. The skin may appear normal or be accompanied by erythema. Sensitive skin affects all parts of the body, especially the face "(1).

It has been recognized that environmental factors (such as exposure to ultraviolet radiation, air pollution, climate (hot, cold, wind)), or lifestyle (dietary or cosmetic habits), or physiological factors (such as stress, endogenous hormones) potentially induce or exacerbate the symptoms of sensitive skin (2). Two main causes may explain the symptoms of sensitive skin: firstly, the permeability of the stratum corneum is increased and secondly, the neural response is accelerated (3).

Indeed, several studies have demonstrated that there is a link between sensitive skin and disruption of barrier function, resulting in skin discomfort. The deterioration of barrier function is also associated with atopic dermatitis, and it has been shown that atopy in skin-sensitive people is increased in incidence and the risk of developing allergy is higher. Finally, people with atopic dermatitis reported to be skin sensitive, with 80% reporting moderate to very sensitive. These data indicate that there may be a link between atopic dermatitis and sensitive skin (2).

In addition, according to the sensation described in sensitive skin, it is highly likely that sensitive skin exhibits neurosensory dysfunction in which nerve endings at the skin surface are less protected due to deterioration of the skin barrier or they are overreactive. Cutaneous nerve fibers (e.g., unmyelinated C fibers) induce especially the sensation of pain and itch and have sensory nerve receptors (e.g., TRP (transient receptor potential) channels) on their surface, which are known to induce pain, burning and itching sensations in sensitive skin (3).

Specifically, TRPA1 (transient receptor potential ankyrin 1) is a nociceptor channel that is present on the surface of C fibers as well as keratinocytes, melanocytes, and fibroblasts, and that can be activated by a number of exogenous factors (low temperature, components of mustard oil (including AITC or allyl isothiocyanate), environmental pollutants, certain itch initiators, etc.) and endogenous factors (active oxygen, nitric oxide, lipid oxidation products). It is also under the control of intracellular sensitization processes involving several inflammatory mediators, such as growth factors, bradykinin, certain proteases and cytokines (4).

TRPA1 is involved in a number of physiological and cellular processes in humans (including nociception), particularly in response to chemical stimuli, itching/pruritus, neurogenic inflammation and heat sensation (5). For example, TRPA1 is involved in transmitting histamine-independent sensations of itch to the central nervous system. In the lesions of patients with atopic dermatitis, TRPA1 expression in nerve terminals was high. TRPA1 is also associated with the itching/pruritus cycle induced in dry skin, consistent with the fact that TRPA1 is an essential sensor for attacking the skin barrier (6).

The appearance of signs of discomfort within minutes after the subject has been in contact with the trigger element is one of the basic features of sensitive skin that exhibits neurosensory dysfunction.

These signs of discomfort are primarily sensory disturbances. "sensory disorder" is understood to mean a more or less painful sensation perceived in an area of the skin, such as stinging, tingling, itching, burning, fever, discomfort, tightness.

Cosmetic and/or dermatological and/or nutritional compositions which can be applied orally or topically and which can be used to prevent or slow down the appearance of sensory disorders, more particularly stinging, tingling, itching, tautness, on sensitive skin. They generally comprise a fatty phase consisting of at least one oil of vegetable, animal, mineral or synthetic origin. Among these oils, vegetable oils are widely used because the market trend is toward the use of products derived from nature.

Vegetable oils are mainly composed of triglycerides, are characterized by various properties of the fatty chain and make it possible, after glycerolysis, to obtain a characteristic distribution of the fatty carboxylic acids.

Thus, vegetable oils differ from plant essential oils in that essential oils are aromatic products that are typically obtained from plant materials by steam distillation. Thus, essential oils extracted from plants do not contain fatty triglycerides.

Of these fatty carboxylic acids present in vegetable oils in the form of triglycerides, petroselinic acid or (Z) -octadec-6-enoic acid is known for the treatment or prevention of skin or scalp disorders. International patent application publication No. WO 99/02149 a1 describes in particular its use against psoriasis-related inflammation, erythema (sunburn), eczema, seborrheic dermatitis, alopecia areata, mycoses, acne or other skin disorders. These applications may also extend to inflammation of the eye (inflammation of the cornea) and of the mucous membranes, in particular of the oral, nasal, buccal and vaginal mucosa. International patent application publication No. WO 99/02149 a1 also describes that a composition comprising petroselinic acid may be administered orally so that petroselinic acid may act on the mucous membranes (buccal, esophageal, gastric and intestinal) and/or it may enter the bloodstream and be delivered directly to the skin, eye or mucosal cells.

Petroselinic acid is more particularly present in oils derived from plants of the Umbelliferae family (plants whose flowers are arranged in an umbrella shape).

In the cosmetic field, coriander has been used as an ingredient in traditional ayurvedic cosmetic formulations (varnakallepa) to normalize skin colour (7). On the other hand, these effects relate to coriander essential oil instead of coriander seed oil (8).

The effect of coriander is known, in particular on the skin: the inflammatory effects of coriander essential oil are described (9).

Powder from coriander seeds showed in vivo anti-inflammatory effects in an inflammatory model of carrageenan-induced edema in rats (10). Although coriander oil showed free radical scavenging in vitro, it did not show anti-inflammatory effects in the same in vivo model as above (11).

According to the same study model, coriander oil failed to reduce rat paw edema (12).

Coriander extracts obtained by extraction with hexane or methanol show in vitro activity against cyclooxygenase-1 and-2 (13). However, the signaling pathways involved between the activation of the cyclooxygenase/lipoxygenase enzyme on the one hand and the sensory neurons on the other hand are not relevant and no effect on itching, itching or discomfort was observed or demonstrated.

European patent application publication No. EP 0888773 a1 relates to the use of petroselinic acid for treating superficial tissue inflammation, in particular for preparing a composition intended to activate peroxisomal β -oxidation of fatty acids in superficial tissues of mammals so as to be able to treat or prevent inflammation of superficial tissues and/or to modulate lipid metabolism of superficial tissues, which was abandoned as the prior art is considered too large. However, the use of coriander seed oil for preventing and/or reducing the discomfort caused by sensitive or reactive skin, and in particular itching, stinging, tingling, itching or tightness, is not described in EP 0888773 a 1.

US patent publication US 6365175 relates to the use of petroselinic acid in the food field, in particular for the preparation of a food supplement composition for use as an anti-inflammatory composition or as an anti-ageing composition, which inhibits the production of arachidonic acid metabolites and/or reduces the formation of intracellular adhesion molecules. However, there is no disclosure or teaching in US 6365175 of the use of coriander seed oil for preventing and/or reducing the discomfort caused by sensitive or reactive skin, in particular itching, stinging, tingling, itching or tightness.

In their scope of research on the treatment of sensory disorders in sensitive human skin, the inventors have focused on the development of novel compositions having a positive effect on sensitive skin.

In a first aspect, the present invention provides the use of at least one oil from at least one seed of an Umbelliferae plant as a cosmetic active ingredient which can be topically applied for preventing or slowing down the appearance of sensory disorders on the skin of a sensitive person.

In the context of the present application, "sensory disorder" is understood to mean a sensation felt in an area of the skin, such as prickling, tingling, itching, burning, fever, or tightness.

The oil from such seeds of Umbelliferae is obtained by carrying out a process comprising at least one step of grinding the seeds and/or at least one step of pressing the seeds, and at least one subsequent step of refining the oily liquid obtained after the grinding and/or pressing step.

Coriander seed oil is preferably used.

The use according to the invention may, as the case may be, have one or more of the following features:

-the plant of Umbelliferae is selected from coriander, centella asiatica (chervil), celery, cumin, carrot, dill, parsley (parsley) and fennel,

-the plant of the Umbelliferae family is coriander,

-the oil from seeds of Umbelliferae plants comprises, per 100% of its weight, greater than or equal to 99% of at least one triglyceride which is a compound having formula (I):

R₁-C(＝O)-O-CH₂-CH[O-C(＝O)-R₁]-CH₂-O-C(＝O)-R₁ (I)

wherein R is₁-C (═ O) -acyl groups which are members selected from the group consisting of: palmitoyl (or hexadecanoyl), stearoyl (or octadecanoyl), petroseloyl (or (Z) -octadeca-6-enoyl), oleyl (or cis-octadeca-9-enoyl) and linoleyl (or cis, cis-9, 12-octadecadienoyl), linolenoyl (or (9Z,12Z,15Z) -9,12, 15-octadecatrienooyl),

-the oil from seeds of Umbelliferae plants comprises triglycerides of formula (I) in an amount of between 40% and 85% by weight, more particularly between 55% and 80% by weight, and still more particularly between 60% and 75% by weight, per 100% of its weight of triglycerides of formula (I), wherein the group R1C (═ O) -is petroselinyl (or (Z) -octadeca-6-enoyl),

-the oil from seeds of Umbelliferae plants comprises, per 100% of its weight, triglycerides of formula (I): a triglyceride of formula (I) in an amount between 2 and 5 wt%, wherein the group R1C (═ O) — is palmitoyl; and/or triglycerides of formula (I) in an amount between 0 and 1.5 wt%, wherein the group R1C (═ O) -is stearoyl; and/or a triglyceride of formula (I) in an amount between 60 and 75 wt%, wherein the group R1C (═ O) -is petroselinyl (or (Z) -octadeca-6-enoyl); and/or triglycerides of formula (I) in an amount between 8 and 15 wt%, wherein the group R1C (═ O) — is oleyl; and/or triglycerides of formula (I) in an amount between 12 and 19 wt%, wherein the group R1C (═ O) — is linoleoyl; and/or triglycerides of formula (I) in an amount between 0 and 1 wt%, wherein the group R1C (═ O) — is linolenoyl.

The invention also provides a cosmetic or dermatological formulation for topical use, comprising, per 100% by weight thereof:

-from 0.5 to 50% by weight of at least one oil from seeds of Umbelliferae plants as defined in one of claims 1 to 6, and

-from 50% to 99.5% by weight of at least one cosmetically acceptable ingredient.

The expression "cosmetically acceptable" used in the definition of a cosmetic formulation for topical use means any substance or formulation intended to come into contact with the parts of the human body (epidermis, body hair and hair system, nails, lips and genitals) or with the teeth and oral mucosa (for the purpose of cleaning them, perfuming them, modifying their appearance and/or correcting their body odor and/or protecting them or keeping them in good condition) according to the european economic community council directive No. 76/768/EEC of 1976-27, revised by directive No. 93/35/EEC of 6-14-1993.

As the case may be, the formulation according to the invention may have one or more of the following characteristics:

-in the form of an aqueous or hydro-alcoholic or hydro-glycol solution, or in the form of a suspension, emulsion, microemulsion or nanoemulsion, whether they are of the water-in-oil, oil-in-water, water-in-oil-in-water or oil-in-water-in-oil type, or in the form of a powder.

It is packaged in a bottle, in a device of the pump "bottle" type, in an aerosol device in pressurized form, in a device equipped with a hollowed-out wall such as a grille, or in a device equipped with a ball applicator.

-the cosmetically acceptable ingredient is an excipient and/or an active ingredient.

-the excipients and/or active ingredients are selected from thickening and/or gelling surfactants, stabilizers, film-forming compounds, hydrotropes, plasticizers, emulsifiers and co-emulsifiers, opacifiers, pearlizing agents, superfatting agents, sequestrants, chelating agents, antioxidants, perfumes, preservatives, conditioning agents, whitening agents intended for bleaching body hair and skin, active ingredients intended to aid the treatment effect with respect to skin or hair, sunscreens, mineral fillers or pigments, particles providing a visual effect or intended for encapsulating active ingredients, exfoliating particles and texturing agents.

As examples of foaming and/or detergent surfactants which can be combined with the cosmetic formulations for topical use subject matter of the present invention as defined above, mention may be made of anionic, cationic, amphoteric or nonionic foaming and/or detergent surfactants.

Among the anionic lathering and/or detergent surfactants that can be combined with the subject of the invention for topical formulations as defined above, mention may be made of alkyl ether sulfates, alkyl sulfates, alkylamidoether sulfates, alkylaryl polyether sulfates, monoglyceride sulfates, alpha-olefin sulfonates, paraffin sulfonates, alkyl phosphates, alkyl ether phosphates, alkyl sulfonates, alkylamide sulfonates, alkylaryl sulfonates, alkyl carboxylates, alkyl sulfosuccinates, alkyl ether sulfosuccinates, alkylamide sulfosuccinates, alkyl sulfoacetates, alkyl sarcosinates, acyl isethionates, N-acyl taurates, acyl lactylates, N-acylated derivatives of amino acids, N-acylated derivatives of peptides, N-acylated derivatives of proteins, alkyl sulfonates, alkyl sarcosinates, acyl isethionates, N-acyl taurates, acyl lactylates, N-acylated derivatives of amino acids, N-acylated derivatives of peptides, N-, Alkali metal salts, alkaline earth metal salts, ammonium salts, amine salts or aminoalcohol salts of N-acylated derivatives of fatty acids.

Among the amphoteric lathering and/or detergent surfactants that can be combined with the formulations for topical use of the inventive subject matter as defined above, mention may be made of alkyl betaines, alkyl amidobetaines, sulfobetaines, alkyl amidoalkyl sulfobetaines, imidazoline derivatives, phosphate betaines, amphoteric polyacetates and amphoteric propionates.

Among the cationic foaming and/or detergent surfactants that can be combined with the formulations for topical use of the inventive subject matter as defined above, mention may be made in particular of quaternary ammonium derivatives.

Among the nonionic lathering and/or detergent surfactants that can be combined with the formulations for topical use subject of the present invention as defined above, mention may be made more particularly of the alkyl polyglucosides comprising linear or branched and saturated or unsaturated aliphatic groups and comprising from 8 to 16 carbon atoms, such as octyl polyglucoside, decyl polyglucoside, undecylenyl polyglucoside, dodecyl polyglucoside, tetradecyl polyglucoside, hexadecyl polyglucoside or 1, 12-dodecanediyl polyglucoside; ethoxylated hydrogenated castor oil derivatives such as the product sold under the INCI designation "PEG-40 hydrogenated castor oil"; polysorbates, such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 70, polysorbate 80, or polysorbate 85; coconut amide; or an N-alkylamine.

As examples of thickening and/or gelling surfactants that can be combined with the formulations for topical use subject of the invention as defined above, optionally mention may be made of alkoxylated alkylpolyglycoside fatty esters, for example ethoxylated methylpolyglucoside esters, as respectively under the name Glucamate^TMLT and Glumate^TMPEG-120 methyl glucose trioleate and PEG-120 methyl glucose dioleate sold under DOE 120; alkoxylated fatty esters, e.g. under the name Crothix^TMPEG-150 pentaerythritol tetrastearate sold under the name Antil, DS53^TM141 PEG-55CA glycol oleate; or polyalkylene glycol carbamates comprising fatty chains, e.g. under the name Elfacos^TMPPG-14 Laureth Isoveryl dicarbamate sold by T211, or sold under the name Elfacos^TMGT2125 is sold as PPG-14 palmitoleyl polyether 60 hexyl dicarbamate.

As examples of thickening and/or gelling agents that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of copolymers comprising AMPS and alkyl acrylates whose carbon chain contains between four and thirty carbon atoms, and more particularly between ten and thirty carbon atoms; linear, branched or crosslinked terpolymers of at least one monomer bearing a free, partially salified or fully salified strong acid function with at least one neutral monomer and at least one monomer having formula (XIII):

CH2＝C(R'3)-C(＝O)-[CH2-CH2-O]n'-R'4(XIII)

wherein R '3 represents a hydrogen atom or a methyl group, R '4 represents a linear or branched alkyl group containing eight to thirty carbon atoms, and n ' represents a number greater than or equal to 1 and less than or equal to 50.

As examples of thickening and/or gelling agents that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of polysaccharides consisting only of monosaccharides, such as dextran or glucose homopolymers, glucomannan glucans, xyloglucans (glucomannans), galactomannans in which the Degree of Substitution (DS) of the D-galactose units on the main D-mannose chain is between 0 and 1, and more particularly between 1 and 0.25, such as galactomannans derived from cassia gum (DS ═ 1/5), locust bean gum (DS ═ 1/4), tara gum (DS ═ 1/3), guar gum (DS ═ 1/2) or fenugreek gum (DS ═ 1).

As examples of thickening and/or gelling agents that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of polysaccharides consisting of derivatives of monosaccharides, such as sulfated galactans and more particularly carrageenans and agar, oolong sugars (uronans) and more particularly algins, alginates and pectins, heteropolymers of monosaccharides and uronic acids and more particularly xanthan, gellan, gum arabic exudate and karaya gum exudate or glycosaminoglycans.

As examples of thickeners and/or gelling agents that can be combined with the formulations for topical use subject matter of the present invention as defined above, mention may be made of cellulose, cellulose derivatives such as methyl cellulose, ethyl cellulose or hydroxypropyl cellulose, silicates, starch, hydrophilic starch derivatives or polyurethanes.

As examples of stabilizers which can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of microcrystalline waxes, and more particularly waxes, mineral salts such as sodium or magnesium chloride, silicone polymers such as polysiloxane polyalkylpolyether copolymers.

As examples of solvents which can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of water, organic solvents such as glycerol, diglycerol, glycerol oligomers, ethylene glycol, propylene glycol, butylene glycol, 1, 3-propylene glycol, 1, 2-propylene glycol, hexylene glycol, diethylene glycol, xylitol, erythritol, sorbitol, water-soluble alcohols (such as ethanol, isopropanol or butanol), or mixtures of water and said organic solvents.

As examples of spa water or mineral water which can be combined with the preparations for topical use which are the subject of the invention as defined above, mention may be made of spa water or mineral water having a degree of mineralization of at least 300mg/l, in particular Jayan (Avene) water, witel (vitel) water, Vichy basin (Vichysin) water, Equan (Uriae) water, Lifuquan (La Roche-Posay) water, Labuurboule (La Bourboule) water, Anzha lake (Enghien-les-Bains) water, Saint-Gervais-les-Bains) water, Neuriban (N éis-les-Bains) water, Allervain (Allevard-les-Bains) water, Dinieri water, Jie (Saint-Gervali), Nerentz jejune-Bains water, Royle water (Royle-mountain water, Royle water) Saint christita water, Les fumardes water and rosekfield (Tercis-Les-Bains) water.

As examples of hydrotropes which can be combined with the composition for topical use (CE) which is the subject of the invention as defined above, mention may be made of xylene sulfonate, cumene sulfonate, hexyl polyglucoside, 2-ethylhexyl polyglucoside or n-heptyl polyglucoside.

As examples of emulsifying surfactants that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of nonionic, anionic or cationic surfactants.

As examples of nonionic emulsifying surfactants which can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of esters of fatty acids and of sorbitol, for example under the name Montane^TM 40、Montane^TM 60、Montane^TM 70、Montane^TM80 and Montane^TM85 products sold; compositions comprising glyceryl stearate and between 5 and 150 moles of ethylene oxide ethoxylated stearic acid, such as compositions comprising 135 moles of ethylene oxide ethoxylated stearic acid and glyceryl stearate (under the name Simulsol^TM165 sale); dehydrated mannitol ester; ethoxylated anhydromannitol esters; sucrose esters; methyl glucose

An ester; alkylpolyglycosides containing linear or branched and saturated or unsaturated aliphatic groups and containing from 14 to 36 carbon atoms, such as tetradecylpolyglucoside, hexadecylpolyglucoside, octadecylpolyglucoside, hexadecylxyloside, octadecylpolyxyloside, eicosylpolyglucoside, dodecylpolyglucoside, 2-octyldodecylxyloside or 12-hydroxystearylpolyglucoside; compositions comprising a linear or branched and saturated or unsaturated fatty alcohol of 14 to 36 carbon atoms and an alkyl polyglycoside as described above, for example under the name Montanov^TM 68、Montanov^TM 14、Montanov^TM 82、Montanov^TM 202、Montanov^TM S、Montanov^TM WO18、Montanov^TM L、Fluidanov^TM20X and Easyov^TMA composition for sale.

As examples of anionic surfactants that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of glycerol citrate stearate, cetearyl sulfate, soaps such as sodium stearate or triethanolammonium stearate, or N-acylated derivatives of salified amino acids (e.g. stearoyl glutamate).

As examples of emulsifying cationic surfactants that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of amine oxides, quaternary ammonium salts-82 and the surfactants described in patent application WO 96/00719, and mainly surfactants comprising at least 16 carbon atoms in their fatty chain.

As examples of opacifiers and/or pearlescers that can be combined with the formulations for topical use subject matter of the present invention as defined above, mention may be made of sodium palmitate, sodium stearate, sodium hydroxystearate, magnesium palmitate, magnesium stearate, magnesium hydroxystearate, ethylene glycol monostearate, ethylene glycol distearate or fatty alcohols containing from 12 to 22 carbon atoms.

As examples of texture agents that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of N-acylated derivatives of amino acids, for example under the name of Aminohope^TMLL, sold under the name Dryflo^TMOctenyl starch succinate sold under the name Montanov^TM14, myristyl polyglucoside, cellulose fiber, cotton fiber, chitosan fiber, talc, sericite or mica.

As deodorants which can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of alkali metal silicates; zinc salts such as zinc sulfate, zinc gluconate, zinc chloride or zinc lactate; quaternary ammonium salts, such as cetyl trimethyl ammonium salt or cetyl pyridinium salt; glycerol derivatives, such as glycerol caprate, glycerol caprylate or polyglycerol caprate; 1, 2-decanediol; 1, 3-propanediol; salicylic acid; sodium bicarbonate; a cyclodextrin; a metal zeolite; triclosan (Triclosan)^TM(ii) a Aluminium bromide hydrate, aluminium chlorohydrate, aluminium chloride, sulphurAluminum acid, aluminum zirconium chlorohydrate, aluminum zirconium trichloride hydrate, aluminum zirconium tetrachloride hydrate, aluminum zirconium pentachloride hydrate, aluminum zirconium octachloride hydrate, aluminum sulfate, sodium aluminum lactate, or a complex of aluminum chlorohydrate and a glycol, such as a complex of aluminum chlorohydrate and propylene glycol, a complex of aluminum dichlorohydrate and propylene glycol, a complex of aluminum chlorohydrate and polyethylene glycol, a complex of aluminum dichlorohydrate and polyethylene glycol, or a complex of aluminum chlorohydrate and polyethylene glycol.

As examples of oils that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of mineral oils, such as liquid paraffin, liquid petrolatum, isoparaffins or white mineral oil; oils of animal origin, such as squalene or squalane; vegetable oils, such as squalane, sweet almond oil, coconut oil, castor oil, jojoba oil, olive oil, rapeseed oil, peanut oil, sunflower oil, wheat germ oil, corn germ oil, soybean oil, cottonseed oil, alfalfa oil, poppy seed oil, pumpkin seed oil, evening primrose oil, millet oil, barley oil, rye oil, safflower oil, tung oil, passion fruit oil, hazelnut oil, palm oil, shea butter, almond oil, tung oil (calophyllum oil), garlic mustard oil (sisymbrium oil), avocado oil, calendula oil, oils derived from flowers or vegetables, or ethoxylated vegetable oils; synthetic oils, such as fatty acid esters, such as butyl myristate, propyl myristate, isopropyl myristate, cetyl myristate, isopropyl palmitate, octyl palmitate, butyl stearate, cetyl stearate, isopropyl stearate, octyl stearate, isocetyl stearate, lauryl oleate, hexyl laurate, propylene glycol dicaprylate, esters derived from lanolin acids (such as isopropyl lanolate or isocetyl lanolate), monoglycerides of fatty acids, diglycerides and triglycerides (such as glycerol triheptate), alkyl benzoates, hydrogenated oils, poly (alpha-olefins), polyolefins (such as poly (isobutane)), synthetic isoalkanes (such as isohexadecane or isododecane), or perfluorinated oils; silicone oils such as dimethylpolysiloxane, methylphenylpolysiloxane, silicone modified by amine, silicone modified by fatty acid, silicone modified by alcohol and fatty acid, silicone modified by polyether group, silicone modified by epoxy, silicone modified by fluorinated group, cyclic silicone, and silicone modified by alkyl group. In the present patent application, the term "oil" refers to a compound and/or a mixture of compounds that is water-insoluble and has the appearance of a liquid at a temperature of 25 ℃.

As examples of waxes that can be combined with the formulations for topical use of the inventive subject matter as defined above, mention may be made of beeswax, carnauba wax, candelilla wax, ouricury wax, japan wax, cork fibre wax, sugar cane wax, paraffin wax, montan wax, microcrystalline wax, lanolin wax; ozokerite; polyethylene wax; a silicone wax; a vegetable wax; fatty alcohols and fatty acids that are solid at ambient temperature; or glycerides that are solid at ambient temperature. In the present patent application, the term "wax" refers to a compound and/or a mixture of compounds that is water-insoluble and has a solid appearance at a temperature greater than or equal to 45 ℃.

As examples of active ingredients that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of vitamins and their derivatives, in particular their esters, such as retinol (vitamin a) and its esters (e.g. retinyl palmitate), ascorbic acid (vitamin C) and its esters, sugar derivatives of ascorbic acid (e.g. ascorbyl glucoside), tocopherol (vitamin E) and its esters (e.g. tocopherol acetate), vitamin B3 or B10 (niacinamide and its derivatives); compounds exhibiting a whitening or depigmenting effect on the skin, e.g. under the name Sepiwhite^TM MSH、Sepicalm^TMOmega-undecylenoyl phenylalanine sold by VG, mono-and/or diglycerides of omega-undecylenoyl phenylalanine, omega-undecylenoyl dipeptides, arbutin, kojic acid, hydroquinone; compounds exhibiting soothing action, in particular Sepicalm^TMS, allantoin and bisabolol; an anti-inflammatory agent; compounds exhibiting moisturizing effect, such as urea, hydroxyurea, glycerol, polyglycerol, glycerol glucoside, diglycerol glucoside, polyglycerol glucoside, xylitol glucosideGlucoside; polyphenol-rich plant extracts such as grape extract, pine extract, wine extract or olive extract; compounds exhibiting slimming or lipolytic action, e.g. caffeine or derivatives thereof, Adiposlim^TM、Adipoless^TMFucoxanthin; an N-acylated protein; n-acylated peptides, e.g. Matrixyl^TM(ii) a An N-acylated amino acid; a partial hydrolysate of an N-acylated protein; an amino acid; a peptide; total hydrolysis products of proteins; soybean extracts, e.g. Rafferamine^TM(ii) a Wheat extracts, e.g. Tensine^TMOr Gliadine^TM(ii) a Plant extracts, such as tannin-rich plant extracts, isoflavone-rich plant extracts or terpene-rich plant extracts; extract of fresh water algae or seaweed; marine plant extracts; marine extracts, typically coral; essential wax (essential wax); a bacterial extract; a ceramide; a phospholipid; compounds exhibiting antimicrobial or scavenging action, e.g. Lipacide^TMC8G、Lipacide^TM UG、Sepicontrol^TM A5、Octopirox^TMOr Sensiva^TMSC 50; compounds exhibiting exciting or stimulating properties, e.g. physiogenol^TMPanthenol and derivatives thereof such as Sepicap^TMMP; anti-ageing active ingredients, e.g. Sepilift^TM DPHP、Lipacide^TM PVB、Sepivinol^TM、Sepivital^TM、Manoliva^TM、Phyto-Age^TM、Timecode^TM；Survicode^TM(ii) a An anti-photoaging active ingredient; an active ingredient that protects the integrity of the dermal-epidermal junction; active ingredients that increase the synthesis of extracellular matrix components, such as collagen, elastin, or glycosaminoglycans; an active ingredient that advantageously acts on chemical cellular communication, such as a cytokine, or an active ingredient that advantageously acts on physical cellular communication, such as an integrin; active ingredients that produce a "heating" sensation on the skin, such as skin microcirculation activators (e.g., nicotinic acid derivatives) or products that produce a "cooling" sensation on the skin (e.g., menthol and derivatives); active ingredients that improve the microcirculation of the skin, such as, for example, intravenous tensides (venotonics); a drainage active ingredient; effective component with decongestant effect, such as semen Ginkgo (Ginkgo b)iloba), ivy, horse chestnut, bamboo, Ruscus (Ruscus), caragana (butcher's broom), Centella asiatica (Centella asiatica), lichen (fucus), rosemary or willow extract; agents for tanning or tanning the skin, such as Dihydroxyacetone (DHA), erythrulose, meso-tartaric aldehyde, glutaraldehyde, glyceraldehyde, alloxan (alloxan) or ninhydrin, plant extracts, such as rosewood extracts of the genera Pterocarpus and Baphia (Baphia), such as Pterocarpus santalinus (Pterocarpus santalinus), Pterocarpus africanus (Pterocarpus osun), Pterocarpus shaoxinus (Pterocarpus soyauxii), Pterocarpus hedgehog (Pterocarpus inerlus), Pterocarpus indicus (Pterocarpus indicus) or Pterocarpus marsupium (Baphia nitida), such as those described in european patent application EP 0971683; agents known for their action of promoting and/or accelerating tanning or tanning of human skin and/or for their action of coloring human skin, such as carotenoids (and more particularly β -carotene and γ -carotene), products sold under the trade name Carros Oil (INCI name: carrot (Daucus carota), sunflower Oil) by the company Provital, which contain carotenoids, vitamin E and vitamin K; tyrosine and/or derivatives thereof, known for their effect in accelerating tanning of human skin in combination with exposure to ultraviolet radiation, for example by the company Provital under the trade name SunTan accumulator^TMA product sold containing tyrosine and riboflavin (vitamin B); complexes of tyrosine and tyrosinase sold under the trade name Zymo Tan Complex by Zymo Line; by Mibelle under the trade name MelanoBronze^TM(INCI name: acetyltyrosine, product sold by Vitex agnus-castus extract (Vitex agnus-castus)), which contains acetyltyrosine; products sold by the company Unipex under the trade name Unipertan VEG-24/242/2002(INCI name: butylene glycol and acetyl tyrosine and hydrolyzed vegetable proteins and adenosine triphosphate); by Sederma under the trade name Try-Excell^TM(INCI name: oleoyl tyrosine and Luffa cylindrica extracts (seed oil and oleic acid) sold under the name of vegetable oil, which contains the extract of the seeds of Cucurbita pepo (or Luffa cylindrica oil); Actibroze under the trade name of Alban Muller, Inc.)^TM(INCI name: hydrolyzed wheat protein and BAcyl tyrosine and copper gluconate); tyrostan under the trade name Synerga^TM(INCI name: potassium hexanoyl tyrosinase); products sold under the trade name Tyrosinol (INCI name: sorbitan isostearate, glyceryl oleate, caproyl tyrosine) by Synerga; InstaBronze, trade name, by Alban Muller^TM(INCI name: dihydroxyacetone and acetyl tyrosine and copper gluconate); products sold under the trade name Tyrosilane (INCI name: methyl silanol and acetyl tyrosine) by Exymol corporation; peptides known for their melanogenesis activation, for example the product sold under the trade name Bronzing SF peptide powder (INCI name: dextran and octapeptide-5) by Infinitec Activos, the product sold under the trade name Melitane (INCI name: glycerol and water and dextran and acetyl hexapeptide-1) comprising acetyl hexapeptide-1 known for their alpha-MSH agonist action, the product sold under the trade name matrices Solutions by Lipotec^TM(INCI name: butanediol, palmitoyl tripeptide-40), sugars and sugar derivatives, e.g. from Provision under the trade name Tanositol^TM(INCI name: inositol) under the trade name Thalitan by CODIF International (CODIF International)^TM(or Phycosaccharide)^TMAG) under the market (INCI name: water and hydrolyzed algin (Laminaria digitata) and magnesium and manganese sulfates) containing marine-derived oligosaccharides (guluronic and mannuronic acids chelated with magnesium and manganese ions) produced by Alban Muller under the trade name Melaciva^TMProducts sold under the INCI name maltodextrin, Mucuna pruriens seed extract, flavonoid-rich compounds such as those sold under the trademark "Biotanning" by Silab (INCI name: hydrolyzed Citrus sinensis fruit extract) and known to be rich in lemon flavonoids (hesperidin type); agent intended for treating hair and/or body hair, for example an agent for protecting the melanocytes of hair follicles, a cytotoxic agent intended to protect said melanocytes from being responsible for the senescence and/or apoptosis of said melanocytes, a mimetic of the activity of dopachrome tautomerase, such as those described in the european patent application published under the number EP 1515688 a2Synthetic SOD mimicking molecules such as manganese complexes, antioxidant compounds such as cyclodextrin derivatives, silica containing compounds derived from ascorbic acid, lysine pyrrolidone carboxylate or arginine pyrrolidone carboxylate, combinations of mono-and diesters of cinnamic acid and vitamin C, and more generally those mentioned in the european patent application published under the number EP 1515688 a 2.

As examples of antioxidants that can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of EDTA and its salts, citric acid, tartaric acid, oxalic acid, BHA (butylhydroxyanisole), BHT (butylhydroxytoluene), tocopherol derivatives such as tocopherol acetate, mixtures of antioxidant compounds, for example known by the company akzo nobel (akzo nobel) under the INCI name: dissolvine GL 47S sold under tetrasodium glutamate diacetate.

As examples of sunscreens which can be combined with the formulations for topical use subject of the present invention as defined above, mention may be made of all the sunscreens which appear in the revised cosmetic instructions 76/768/EEC, appendix VII.

Among the organic sunscreens which can be combined with the formulations for topical use subject of the invention as defined above, mention may be made of a family of benzoic acid derivatives, such as p-aminobenzoic acid (PABA), in particular the monoglycerides of PABA, the ethyl ester of N, N-dipropoxyppaba, the ethyl ester of N, N-diethoxyppaba, the ethyl ester of N, N-dimethyl PABA, the methyl ester of N, N-dimethyl PABA, or the butyl ester of N, N-dimethyl PABA; a family of anthranilic acid derivatives, such as trimethylcyclohexyl N-acetyl anthranilate; a family of salicylic acid derivatives, such as amyl salicylate, trimethylcyclohexyl salicylate, ethylhexyl salicylate, phenyl salicylate, benzyl salicylate, or p-isopropyl phenyl salicylate; a family of cinnamic acid derivatives, such as ethylhexyl cinnamate, ethyl 4-isopropylcinnamate, methyl 2, 5-diisopropylcinnamate, propyl p-methoxycinnamate, isopropyl p-methoxycinnamate, isoamyl p-methoxycinnamate, octyl p-methoxycinnamate (2-ethylhexyl p-methoxycinnamate), p-methoxycinnamate2-ethoxyethyl acid, cyclohexyl p-methoxycinnamate, ethyl α -cyano- β -phenylcinnamate, 2-ethylhexyl α -cyano- β -phenylcinnamate, or di (p-methoxycinnamate) mono (2-ethylhexanoyl) glyceride; families of benzophenone derivatives, such as 2, 4-dihydroxybenzophenone, 2' -dihydroxy-4-methoxybenzophenone, 2',4,4' -tetrahydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4 ' -methylbenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, 4-phenylbenzophenone, 2-ethylhexyl 4' -phenylbenzophenone-2, 5-dicarboxylate, 2-hydroxy-4- (n-octyloxy) benzophenone, 4-hydroxy-3-carboxybenzophenone; 3- (4' -methylbenzylidene) -d, l-camphor, 3-benzylidene-d, l-camphor, camphorbenzalkonium methosulfate; urocanic acid, ethyl urocanic acid; a family of sulfonic acid derivatives, such as 2-phenylbenzimidazole-5-sulfonic acid and salts thereof; family of triazine derivatives, for example hydroxyphenyltriazine, ethylhexyloxyphenyl4-methoxyphenyl-triazine, 2,4, 6-triphenylamine (trianilino) (p-C-2 ' -ethylhexyl-1 ' -oxy) -1,3, 5-triazine, 4- ((6- (((1, 1-dimethylethyl) amino) carbonyl) phenyl) amino) -1,3, 5-triazine-2, 4-diyldiimino) bis (2-ethylhexyl) ester of benzoic acid, 2-phenyl-5-methylbenzoxazole, 2' -hydroxy-5-methylphenylbenzotriazole, 2- (2' -hydroxy-5 ' - (tert-octyl) phenyl) benzotriazole, 2- (2 '-hydroxy-5' -methylphenyl) benzotriazole; dibenzo nitrogen

(dibenzazine); di-p-methoxybenzoyl methane, 4-methoxy-4' -tert-butylbenzoyl methane; 5- (3, 3-dimethyl-2-norbornene) -3-pentan-2-one; a family of diphenylacrylate derivatives, such as 2-ethylhexyl-2-cyano-3, 3-diphenyl-2-acrylate or ethyl 2-cyano-3, 3-diphenyl-2-acrylate; or those of the polysiloxane family, such as benzylidene siloxane malonates.

Among the inorganic sunscreens (also known as "mineral sunscreens") which can be combined with the formulations for topical use of the subject of the invention as defined above, mention may be made of titanium oxide, zinc oxide, cerium oxide, zirconium oxide, yellow, red or black iron oxide, or chromium oxide. These mineral sunscreens may or may not be micronized, may or may not be subjected to surface treatment and may optionally be supplied in the form of aqueous or oily pre-dispersions.

The present invention also provides a method for preventing or slowing down the appearance of sensory disorders in sensitive human skin, which comprises at least one step a) of applying an effective amount of a cosmetic formulation as defined above to the skin surface to be treated.

In the definition of the above method, the term "effective amount" means an increase of the reduction of paresthesia on human skin of at least 25% after a period of between seven days and twenty-one days after application of the formulation to the epidermis to be treated, relative to that measured before application of the formulation as defined above to the epidermal surface of the skin to be treated.

The method preferably comprises a step b) of massaging the skin surface to be treated.

Finally, the invention also provides:

-a seed oil from at least one Umbelliferae plant as defined above for use in therapeutic treatment aimed at preventing or slowing down the appearance of sensory disorders on the skin of sensitive humans.

-a formulation as defined above for use in therapeutic treatment aimed at preventing or slowing down the appearance of sensory disorders on sensitive human skin.

Bibliography:

(1):“Definition of Sensitive Skin:An Expert Position Paper from the Special Interest Group on Sensitive Skin of the International Forum for the Study of Itch”.Misery,

Szepietowski,Reich,Wallengren,Evers,Takamori,Brenaut,Le Gall-Ianotto,Fluhr,Berardesca,Weisshaar.Acta Derm Venereol.2017 Jan 4；97(1):4-6)

(2):“Sensitive skin”.Misery,Loser,

J Eur Acad Dermatol Venereol.2016 Feb；30 Suppl 1:2-8

(3):“Putative neuronal mechanisms of sensitive skin.”

Schneider,Weishaupt,Luger,Misery.Exp Dermatol.2009May；18(5):417-23.

(4):“TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation:pro-inflammatory response induced by their activation and their sensitization.”Gouin,L'Herondelle,Lebonvallet,Le Gall-Ianotto,Sakka,Buhé,Plée-Gautier,Carré,Lefeuvre,Misery,Le Garrec.Protein Cell.2017 Sep；8(9):644-661

(5):“Regulation of Pain and Itch by TRP Channels”.Moore,Gupta,Jordt,Chen,Liedtke.Neurosci Bull.2018 Feb；34(1):120-142

(6):“Mediators of Chronic Pruritus in Atopic Dermatitis:Getting the Itch Out？”Mollanazar NK,Smith PK,Yosipovitch G.Clin Rev Allergy Immunol.2016 Dec；51(3):263-292

(7):Yadav&Chaudhary.“Cosmeceutical assets of ancient and contemporary ayurvedic astuteness”.Int J Green Phar 2015,9:S1-S6

(8):Coriander(Coriandrum sativum):“A promising functional food toward the well-being”.Prachayasittikul,Prachayasittikul,Ruchirawat.Food Res Int 2018.105:305-323.

(9):“Anti-inflammatory potential of a lipolotion containing coriander oil in the ultraviolet erythema test.”Reuter,Huyke,Casetti,Theek,Frank,Augustin,Schempp.J Dtsch Dermatol Ges.2008Oct；6(10):847-51.

(10):“Study of The Anti-Inflammatory Activity of Some Medicinal Edible Plants Growing in Egypt.”Ammar,Al-Okbi,Mohamed.Med J Islamic World Acad Sci.1997；10(4):113-122

(11):“Characterization of antiradical and anti-inflammatory activities of some cold pressed oils in carrageenan-induced rat model of acute inflammation.Attia,Ibrahim,Maklad,Ahmed,Ramadan.Der Pharma Chemica,2016,8(17):148-158”

(12):“Biochemical characterization,anti-inflammatory properties and ulcerogenic traits of some cold-pressed oils in experimental animals”.Ibrahim,Attia,Maklad,Ahmed,Ramadan.Pharm Biol.2017Dec；55(1):740-748),

(13):“Evaluation of coriander spice as a functional food by using in vitro bioassays.”Zhang,Dissanayake,Kevseroglu,Nair.Food Chemistry 2015,167:24-29

the following examples illustrate the invention without limiting it.

The in vitro examples described herein relate to the reduction of the activation of the receptor TRPA1, which receptor TRPA1 is involved in inducing itching/irritation/itching/pain sensations of the skin after certain stimuli.

Prevention of activation of TRPA1 (neuronal expert service)

→Principle of method

Human sensory neurons were obtained from pluripotent stem cells and cultured in culture plates. Human keratinocytes are grown and then seeded over neurons.

After 19 days of CO-culture at 37 ℃ in a humid atmosphere of 5% CO2, 10. mu.M of the test product or positive reference HC030031(C18H21N5O3) and the fluorescent probe Fluo-4 AM were added to the CO-culture. The Fluo-4 AM probe made it possible to track the rapid kinetics of intracellular calcium concentration changes by measuring the cellular fluorescence intensity in real time, and the calcium flux was correlated with the activation of TRPA 1.

After 30 minutes of incubation, the medium was removed and the culture was washed and then re-incubated with the test product. Then, they were immediately placed under an inverted microscope and observed for epifluorescence (epifluorescence). Cells were observed for 3 minutes and photographed approximately every 333 ms. Five seconds after the start of recording, neurons were stimulated with 10-3M AITC (allyl isothiocyanate).

Counting the elements:

the experiment was repeated 6 times. Fluorescence was analyzed for 3 minutes.

Fluorescence values are expressed as mean +/-sem [ standard error of mean-standard deviation/root (number of values) ].

For each condition, the percentages of stimulation and protection were calculated as follows:

% stimulation was 100 × [ mean (condition) ]/[ mean (cells stimulated with AITC) ]

% protection is 100 × [ mean (condition) -mean (cells stimulated with AITC) ]/[ mean (non-stressed cells) -mean (cells stimulated with AITC) ].

Statistical analysis was performed by one-way ANOVA test with pairwise comparison conditions, setting the significance threshold to 5%. The difference between the efficacy of the two products is considered to be:

-significant if p < 0.05;

-if 0.05 ≦ p <0.1, "at significance limit";

and not significant if p > 0.1.

→Results

Table: activation of TRPA1 following AITC stimulation. P <0.001

AITC induced a significant increase in TRPA1 activation in keratinocyte-neuron co-cultures (585% compared to unstimulated cells).

HC30031, an antagonist of TRPA1, significantly reduced 88% activation of TRPA 1. 0.001% coriander seed oil also made it possible to significantly reduce TRPA1 activation by 61%.

→Conclusion

Coriander seed oil is capable of reducing TRPA1 activation in a human keratinocyte-neuron co-culture model.

Claims

1. An oil derived from at least one seed of an Umbelliferae plant, which oil is topically applicable for preventing or alleviating the appearance of sensory disorders in sensitive human skin.

2. An oil according to claim 1, characterized in that the Umbelliferae plant is selected from coriander, clover, celery, cumin, carrot, dill, parsley and fennel.

3. The oil according to claim 1, characterized in that the Umbelliferae plant is coriander.

4. The oil according to any one of claims 1 to 3, characterized in that it comprises, per 100% of its weight, greater than or equal to 99% of at least one triglyceride which is a compound having formula (I):

R₁-C(＝O)-O-CH₂-CH[O-C(＝O)-R₁]-CH₂-O-C(＝O)-R₁ (I)

wherein R is₁-C (═ O) -acyl groups which are members selected from the group consisting of: palmitoyl (or hexadecanoyl), stearoyl (or octadecanoyl), petroseloyl (or (Z) -octadeca-6-enoyl), oleyl (or cis-octadeca-9-enoyl) and linoleyl (or cis, cis-9, 12-octadecadienoyl), linolenoyl (or (9Z,12Z,15Z) -9,12, 15-octadecatrienooyl).

5. The oil according to claim 4, characterized in that it comprises triglycerides of formula (I) in an amount of between 40 and 85 wt. -%, more particularly between 55 and 80 wt. -%, and still more particularly between 60 and 75 wt. -%, wherein the group R1C (═ O) -is petroselyl (or (Z) -octadeca-6-enoyl), per 100% of its weight of triglycerides of formula (I).

6. The oil according to one of claims 4 and 5, characterized in that it comprises, per 100% of its weight, triglycerides of formula (I):

-triglycerides of formula (I) wherein the group R1C (═ O) — is palmitoyl, in an amount between 2 and 5% by weight, and/or

-triglycerides of formula (I) wherein the group R1C (═ O) -is stearoyl, in an amount between 0 and 1.5% by weight, and/or

-triglycerides of formula (I) in an amount between 60 and 75% by weight, wherein the group R1C (═ O) -is petroselinyl (or (Z) -octadeca-6-enoyl), and/or

-triglycerides of formula (I) wherein the group R1C (═ O) -is oleyl, in an amount between 8 and 15% by weight, and/or

-triglycerides of formula (I) wherein the group R1C (═ O) -is linoleoyl, in an amount between 12 and 19% by weight, and/or

-triglycerides of formula (I) in an amount between 0 and 1% by weight, wherein the group R1C (═ O) -is a linolenoyl group.

7. A cosmetic or dermatological formulation for topical use comprising, per 100% of its weight:

8. The cosmetic or dermatological formulation according to claim 7, characterized in that it is in the form of an aqueous or hydro-alcoholic or hydro-glycol solution, or in the form of a suspension, emulsion, microemulsion or nanoemulsion, whether of the water-in-oil, oil-in-water, water-in-oil-in-water or oil-in-water-in-oil type, or in the form of a powder.

9. The cosmetic or dermatological formulation according to claim 8, characterized in that it is packaged in a bottle, in a device of the pump "bottle" type, in an aerosol device in pressurized form, in a device equipped with a hollowed-out wall such as a grille, or in a device equipped with a ball applicator.

10. Cosmetic or dermatological formulation according to one of claims 7 to 9, characterized in that the cosmetically acceptable ingredient is an excipient and/or an active ingredient.

11. The cosmetic or dermatological formulation according to claim 10, characterized in that the excipient and/or active ingredient is selected from thickening and/or gelling surfactants, stabilizers, film-forming compounds, hydrotropes, plasticizers, emulsifiers and co-emulsifiers, opacifiers, pearlescers, superfatting agents, sequestrants, chelating agents, antioxidants, fragrances, preservatives, conditioning agents, whitening agents intended for bleaching body hair and skin, active ingredients intended to aid the treatment effect with respect to skin or hair, sunscreens, mineral fillers or pigments, particles providing a visual effect or intended for encapsulating active ingredients, exfoliating particles and texturing agents.

12. A method for preventing or slowing down the appearance of sensory disorders in sensitive human skin, which method comprises at least one step a) of applying an effective amount of a cosmetic formulation as defined in one of claims 7 to 11 to the skin surface to be treated.

13. The method according to claim 12, characterized in that it comprises a step b) of massaging the surface of the skin to be treated.

14. Oil derived from seeds of at least one Umbelliferae plant as defined in one of claims 1 to 6, for use in therapeutic treatment for the purpose of preventing or slowing the appearance of sensory disorders in the skin of sensitive humans.

15. A formulation as defined in any one of claims 7 to 11 for use in therapeutic treatment for the purpose of preventing or slowing the appearance of sensory disorders on sensitive human skin.